COMPANY
Binary Genomics
We are pursuing applications to enable earlier cancer diagnosis, surveillance of residual or recurrent disease, and real-time monitoring of treatment efficacy. From company website Source · Oct 13, 2026
NIH awards 3
- NIH award 5R44CA285041-03 FY2025: $1,009,228 awarded for that fiscal year; activity R44 (SBIR); PI BARRETT, MICHAEL T; recipient as written: BINARY GENOMICS, INC., Phoenix, AZ. Monitoring Immunotherapy Response via G source ↗
- NIH award 2R44CA285041-02 FY2024: $990,771 awarded for that fiscal year; activity R44 (SBIR); PI BARRETT, MICHAEL T; recipient as written: BINARY GENOMICS, INC., Phoenix, AZ. Monitoring Immunotherapy Response via Gen source ↗
- NIH award 1R43CA285041-01 FY2023: $398,040 awarded for that fiscal year; activity R43 (SBIR); PI BARRETT, MICHAEL T; recipient as written: BINARY GENOMICS, INC., Phoenix, AZ. Monitoring Immunotherapy Response via Gen source ↗